About Calibrium
Calibrium is a company based in Zurich (Switzerland) founded in 2006 by Richard DiMarchi and Fritz French was acquired by Novo Nordisk in August 2015. Calibrium has raised $1.7 million across 1 funding round from investors including Novo Nordisk, Frazier Healthcare Partners and 5AM Ventures. Calibrium operates in a competitive market with competitors including Sana Biotechnology, Kriya Therapeutics, Semma Therapeutics, Cellino and Adocia, among others.
- Headquarter Zurich, Switzerland
- Founders Richard DiMarchi, Fritz French
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.7 M (USD)
in 1 rounds
-
Latest Funding Round
$1.7 M (USD), Seed
Dec 20, 2013
-
Investors
Novo Nordisk
& 3 more
-
Employee Count
Not available
-
Acquired by
Novo Nordisk
(Aug 27, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Calibrium
Calibrium has successfully raised a total of $1.7M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.7 million completed in December 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Calibrium
Calibrium has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Novo Nordisk, Frazier Healthcare Partners and 5AM Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Venture capital fund backed incubator focused on the healthcare startups
|
Locked | Locked | Locked | |
|
BioCrossroads is focused on advancing Indiana's life sciences industry.
|
Locked | Locked | Locked |
Investor details for Calibrium
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Calibrium
Investment portfolio details for Calibrium
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Calibrium
Detailed financials for Calibrium
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Calibrium Comparisons
Peer comparison for Calibrium
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Calibrium
Calibrium operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Kriya Therapeutics, Semma Therapeutics, Cellino and Adocia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Pendulum is focused on developing advanced probiotic solutions.
|
Detailed competitors of Calibrium
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Calibrium
Complete news archive for Calibrium
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Calibrium
Calibrium was founded in 2006 and raised its 1st funding round 7 years after it was founded.
Calibrium is headquartered in Zurich, Switzerland.
Fritz French is the current CEO of Calibrium. They have also founded this company.
Calibrium is a funded company, having raised a total of $1.7M across 1 funding round to date.
Calibrium was founded in 2006 and is based in Zurich, Switzerland. Focus is placed on the discovery and early development of peptide-based therapies targeting diabetes and related metabolic diseases. Operations center on advancing these treatments through preclinical stages within the biotechnology sector. Leadership includes co-founders Richard DiMarchi and Fritz French, with Bernd Kammerlander serving as CEO.
Calibrium's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Calibrium has 4 investors. Key investors include Novo Nordisk, Frazier Healthcare Partners, 5AM Ventures, and BioCrossroads.